Beagles are the most commonly used dog breed in laboratory research, chosen primarily for their small size, gentle temperament, and biological similarities to humans. In fiscal year 2024, over 42,800 dogs were used in research facilities across the United States, according to USDA data, and the vast majority of those were beagles. The breed’s dominance in the lab traces back to the 1950s and reflects a specific combination of practical, biological, and regulatory factors that has kept beagles at the center of pharmaceutical testing for decades.
Temperament and Low Aggression
The single most cited reason beagles end up in labs is their docile nature. Beagles are pack-oriented dogs bred for centuries to work cooperatively with other hounds and with human handlers. In a research setting, this translates to animals that tolerate handling, group housing, and repeated procedures with relatively little resistance. Studies of former laboratory beagles found they showed significantly less aggression toward strangers and other dogs compared to the general pet population. This may partly reflect selective breeding by laboratory suppliers, who specifically breed for low aggression and calm disposition over many generations.
For lab technicians who need to administer compounds orally, draw blood, or conduct imaging on an animal multiple times a day over weeks or months, a cooperative dog reduces both stress on the animal and risk of injury to staff. Larger, more reactive breeds would make these routine procedures far more difficult and dangerous.
The Right Size for the Job
Beagles are small for a hound breed, typically weighing 20 to 30 pounds. This matters enormously in practical terms. Smaller dogs require less of an experimental compound per dose, which saves significant money during early drug development when compounds are expensive to produce. They also need less space, less food, and smaller equipment. A facility housing 60 beagles looks very different from one housing 60 Labrador retrievers, both in cost and logistics. Their size also makes them large enough to provide meaningful physiological data that scales reasonably well to humans, something that smaller animals like mice cannot always offer.
Biological Similarities to Humans
Dogs share key physiological traits with humans that make them valuable for predicting how a drug will behave in the human body. Their cardiovascular system is particularly relevant: the electrical conduction system in a dog’s heart and the way heart muscle remodels under stress closely resemble what happens in human hearts. This makes beagles especially useful for cardiac safety testing, where researchers need to know whether a new drug might cause dangerous heart rhythm changes before it ever reaches human volunteers.
Beyond the heart, dogs process and metabolize many drugs through similar pathways as humans. Pharmacokinetic studies, which track how a drug is absorbed, distributed, broken down, and eliminated, frequently use beagles because the results translate meaningfully to human dosing. Beagles have been used to evaluate drug candidates for diabetes, metabolic diseases, fungal infections, and cancer, among many other conditions. Dogs also develop many of the same cancers humans do at relatively high rates, making them useful models for studying how malignancies form and respond to treatment.
At the genetic level, there is a high degree of overlap between the canine and human genomes. This makes findings in dogs more likely to be relevant to human biology than findings in more distantly related species.
Genetic Consistency Reduces Variability
One of the less obvious reasons beagles dominate laboratory work is genetic uniformity. Dog breeds, by their nature, come from small founder populations and closed breeding pools. This means beagles within a breeding colony are genetically more similar to each other than a random sample of humans would be. For researchers, this is a major advantage: when you reduce genetic variability between test subjects, you can detect the actual effects of a drug or toxin more clearly, with fewer animals needed to reach a statistically meaningful result.
Purpose-bred laboratory beagles take this a step further. Suppliers like Marshall BioResources raise beagles in controlled environments, free of specific pathogens, with known genetic backgrounds and health histories. Researchers can purchase a group of puppies that are the same age, raised under identical conditions, and genetically similar. This level of standardization is nearly impossible to achieve with other large animal models. Genetic association studies in dogs also require fewer subjects and fewer genetic markers than equivalent human studies, because the stretches of shared DNA within a breed are longer and easier to analyze.
Regulatory Pressure for a Non-Rodent Species
Even if a pharmaceutical company wanted to skip dog testing entirely, regulatory frameworks have historically made that difficult. Before a new drug can be tested in humans, agencies like the FDA typically require safety data from at least two animal species, one rodent and one non-rodent. Dogs, and specifically beagles, became the default non-rodent species decades ago. Once a breed becomes entrenched in regulatory practice, an enormous body of historical comparison data accumulates. Researchers know what normal blood values, organ weights, and toxicity responses look like in beagles, making it easier to spot abnormalities caused by a new drug.
The FDA’s Animal Rule, established in 2002, further solidified the role of animal models by requiring that drug effectiveness be demonstrated in animal species “expected to react with a response predictive for humans.” Beagles, with their well-characterized physiology and decades of baseline data, fit this requirement better than almost any alternative.
How Beagles Became the Standard
Beagles weren’t always the go-to lab dog. Their rise began in the 1950s, driven by a convergence of factors. The breed had become popular in the United States as sporting companions during the early twentieth century, which meant breeders were plentiful and puppies were relatively affordable. When the Atomic Energy Commission launched massive radiation longevity experiments in the 1950s at universities including Utah and UC Davis, researchers needed a standardized dog breed they could study over entire lifespans. Beagles, with their manageable size, cooperative nature, and ready availability, were the natural choice.
Around the same time, the emerging field of pharmacokinetics needed a reliable canine model for tracking how drugs move through the body. Purebred beagles entered routine pharmaceutical testing, and as data accumulated, the case for using them only grew stronger. A Harvard doctoral dissertation on the subject notes that beagles’ value came not only from their biological similarities to humans but also because they were “cute, easily trained, and enjoyable to be around,” qualities that mattered to the people working with them daily. Early experimental breeding programs at Cornell, funded by Rockefeller money and supported by pet food corporations, helped establish the infrastructure for producing lab-quality beagles at scale.
What Beagles Are Tested For
The majority of beagles in research are used in toxicology and pharmacology studies. Toxicology testing involves giving animals a compound at various doses to identify what organs it might damage and at what levels. Beagles are considered a gold standard for oral toxicity studies, where a drug is given by mouth, and for cardiovascular safety pharmacology, where researchers monitor heart function in response to a compound.
Of the roughly 42,800 dogs in U.S. research facilities in 2024, about 27,900 were used in procedures involving no pain. Around 12,200 were used in procedures where pain was managed with anesthesia or painkillers. Approximately 410 were involved in procedures where pain was not minimized, typically because pain management would have interfered with the study’s measurements. Another 2,400 dogs were held at facilities but not used in any procedures during the reporting year.
A Shifting Landscape
The legal ground beneath animal testing shifted in December 2022, when President Biden signed the FDA Modernization Act 2.0 into law. This legislation overturned a provision of the 1938 Federal Food, Drug, and Cosmetics Act that had mandated animal testing for every new drug development protocol. The new law allows pharmaceutical companies to use alternatives, including organ-on-a-chip technology, computer modeling, and advanced cell-based assays, in place of animal studies when submitting data to the FDA.
This doesn’t mean beagle testing will disappear overnight. The law permits alternatives but doesn’t ban animal testing, and many companies will continue using beagles where historical data and regulatory familiarity make them the path of least resistance. But for the first time in over 80 years, the legal requirement that once locked dogs into the drug development pipeline is no longer absolute.